Clinical Trial Update: A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating an accelerated vaccination schedule for the recombinant Hepatitis E vaccine produced in Escherichia coli has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis E

Drugs mentioned

• Recombinant Hepatitis E Vaccine (Escherichia coli expression) (Recombinant Hepatitis E Vaccine)

Snippet

Sponsor: Xiamen Innovax Biotech Co., Ltd | Conditions: Hepatitis E | Phase 4 | Status: COMPLETED